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Background: The aim of the present study is to assess the role of endogenous oxytocin (OT) in cardioprotective
effects of ischemic preconditioning (IPC) in anesthetized rat.
Materials and methods: Animals were divided into ﬁve groups: 1) ischemia–reperfusion (IR); (n=6), hearts
were subjected to 25 min regional ischemia and 60 min reperfusion, 2) OT; (n=6), oxytocin was
administered (0.03 μg/kg i.p) 10 min prior to ischemia, 3) IPC; (n=7), IPC was induced via a 5 min regional
ischemia followed by 5 min of reperfusion before IR, 4) IPC+ATO (Atosiban); (n=6), atosiban (1.5 μg/kg i.p)
was used as OT receptor selective antagonist in the beginning of IPC and 5) IR+ATO; (n=6), atosiban was
injected 10 min prior to ischemia–reperfusion.
Results: In our experiment, Infarct size was decreased signiﬁcantly in OT and IPC groups compared to IR (23±
1.5% and 19±0.6% vs. 45±2.9% in IR group, Pb0.05). Administration of atosiban in IPC+ATO group increased
infarct size to 39±0.9% in comparisonwith OT and IPC groups (Pb0.05). The use of OT and IPC prior to ischemia
signiﬁcantly declined ventricular arrhythmias severity in compared to IR group (1.2±0.4 and 1±0.5
respectively, vs. 4±0.4 in IR group, Pb0.05). Blockade of OT receptor by atosiban abolished the
cardiopreconditioning effects of IPC.
Conclusion: This study shows that, in part, the cardioprotective effects of IPC can be induced by endogenous OT.
© 2010 Elsevier B.V. All rights reserved.1. Introduction
Ischemic preconditioning (IPC) of the heart, which was ﬁrst
described by Murry et al. [1], is an extremely complex physiological
and pathophysiological phenomenon, resulting in a protection against
ischemia–reperfusion (IR) injury [2]. Infarct size resulted from a
subsequent sustained ischemia is reduced by brief episodes of
ischemia–reperfusion. This has been conﬁrmed in all species tested
so far [3], and also in humans [4,5]. The signal transduction cascade of
IPC involves mediators such as protein tyrosine kinases, mitogen-
activated protein kinases, protein kinase C and endogenous triggers
such as bradykinin, opioids, adenosine and free radicals [6,7].
Conceptually, triggers are important during the preconditioning
phase, while mediators are important during the sustained ischemia
[8,9]. Themajor effects of cardioprotection are reduction of infarct size
(antinecrotic effect) [10], reduction of number and severity of cardiac
arrhythmias (antiarrhythmic effect) [11,12] and improvement of
contractile performance (protection against contractile dysfunction)
[13].i).
ll rights reserved.More recently, oxytocin (OT) has been considered to be a
cardiovascular hormone [14,15]. OT is produced and released by the
heart and large vessels [16] which acts on its cardiac receptors to
decrease cardiac rate and force of contraction [15]. The multiple
established and proposed actions of OT are all mediated by one type of
OT receptor. This receptor contains seven transmembrane domains
and is a member of the class I family of G protein-coupled receptors
[17,18]. Several studies showed that atosiban is a selective antagonist
of OT receptor and blocks OT effects on tissues [19–21]. Systemic
administration of OT has signiﬁcant effects on blood pressure,
vascular tone and cardiovascular regulation [16]. A major goal of
cardiovascular research is the identiﬁcation of a reliable cardioprotec-
tion intervention that can salvage ischemic myocardium [5]. It has
been suggested that intrinsic OT system may play an important
physiological role in regulating vascular tone, as well as control of
cardiac function [16]. OT is well known to exert potent physiological
anti-stress effects [22] and stress increases the severity of cardiovas-
cular disease [23].
Recently, increasing attention has been given to the potential role of
OT in cardiovascular functions [14,15,24]. Interestingly, it was shown
that OT protects kidney and liver tissues against ischemia–reperfusion
injuries [25,26]. Recently Ondrejcakova et al. reported its protective
effects on ischemia–reperfusion-induced myocardial injury in the
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Fig. 1. Illustration of the experimental protocols. Hearts in all groups were subjected to
25 min of ischemia followed by 60 min reperfusion. NS = normal saline; OT =
oxytocin; IPC = ischemic preconditioning; IS = ischemia; Rep = reperfusion; IR =
ischemia–reperfusion; and ATO = atosiban.
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the ischemic reperfused heart injury [27] and involvement mechanism
[28] in the anesthetized rat. The aim of the present study is to assess the
role of endogenous OT in cardioprotective effects of IPC.
2. Methods and materials
2.1. Animals
Male Sprague–Dawley rats (300–350 g) were maintained in
animal quarters under standardized conditions 12 h light/dark cycle,
20–22 °C ambient temperature and 40–50% humidity with free access
to rat chow and water. All experimental procedures were done
according to the guidelines of the animal and human ethical
committee of Tehran University of medical sciences.
2.2. Surgical preparation
The preparation used in the present study was as described
previously [28]. The animals were anesthetized with sodium
Thiopental (60 mg kg−1, i.p) and maintained with supplementary
doses (~30 mg kg−1, i.p) as required. Body temperature was
measured by rectal thermometer and maintained at 37±1 °C.
The rats were ventilated through a tracheotomy tub with air-and-
oxygen mixture by a rodent ventilator (model 683, Harvard
Apparatus) (stroke volume approximately 1.2 ml 100 g−1, 60–
70 stroke min−1). A positive end-expiratory pressure was applied to
prevent alveolar atelectasis (3–5 cm H2O).
Heparinized catheter (100 U/ml) was ﬁxed into the right carotid
artery for blood sampling and pressure monitoring. The lateral tail
vein was cannulated to inject Evans blue dye and other drugs.
Electrocardiogram standard limb lead-II and arterial blood pressure
were continuously monitored by using a computerized data acquisi-
tion system (Power Lab data acquisition system, four channels, AD
Instruments).
The fourth rib was cut 3 mm below left lateral sternum border. The
pericardium was incised and a sling (6–0 silk Ethicon) was placed
around the left anterior descending (LAD) artery close to its origin
right below the left atrial appendage. Both ends of the ligature were
passed through a small plastic tube. Then the chest was partially
closed and the animals were allowed to recover. Heart rate and blood
pressure were allowed to stabilize for 20 min before the intervention
protocols. To induce transient myocardial ischemia, LADwas occluded
by applying tension to the plastic tube-silk string. Reperfusion was
then initiated by releasing the ligature and removing the tension.
Regional ischemia and reperfusion were conﬁrmed by epicardial
cyanosis and hyperemia, respectively.
2.3. Exclusion criteria
Data were excluded from the ﬁnal analysis if arterial blood
pressure was less than 60 mmHg before treatment or in case of
inadequate blood gas.
2.4. Experimental protocols
The heart of all animals was subjected to 25 min regional ischemia
and 60 min reperfusion (Fig. 1). Animals were divided into ﬁve
groups: 1) IR; (n=6), hearts were subjected to 25 min ischemia and
60 min reperfusion, 2) OT; (n=6), Oxytocin was administered
(0.03 μg/kg i.p) 10 min prior to ischemia [28], 3) IPC; (n=7), IPC
was induced via a 5 min regional ischemia followed by 5 min of
reperfusion before IR, 4) IPC+ATO (Atosiban); (n=6), atosiban
(1.5 μg/kg i.p) was used as OT receptor selective antagonist in the
presence of IPC [28] and 5) IR+ATO; (n=6), atosiban was injected
10 min prior to ischemia–reperfusion.2.5. Hemodynamic functions
Hemodynamic parameters, arterial blood pressure and heart rate
(HR) were continuously monitored and recorded. The rate pressure
product (RPP); systolic blood pressure multiplied by the HR was also
calculated by Power Lab data acquisition system.
2.6. Cardiac area at risk and infarct size determination
To identify area at risk (AAR) the coronary artery was reoccluded.
Evans blue dye (2 ml, 2%) was then injected through lateral tail vein.
The heart was excised; atria and the roots of the great vessels were
removed. Remaining tissues were frozen for 24 h. Then they were cut
into 2 mm slices. All pieces were incubated in 1% solution of 2,3,5-
triphenyltetrazolium chloride (TTC, 0.1 M phosphate buffer, pH 7.4,
Sigma Chemical Co. St. Louis, MO, USA) at 37 °C for 15 min to visualize
the infarct area. Then they were ﬁxed for 2 days in 10% formalin to
enhance the contrast. The non ischemic area, AAR and infarcted area
were colored blue, brick red and pale respectively. Sections were
scanned to determine normal area, AAR and infarct size (IS) by
calculating pixels occupying each area using Adobe PhotoShop
software (Adobe Systems Seattle,WA). Total AAR and IS are expressed
as the percentage of total ventricle and AAR, respectively.
2.7. Assessment of ventricular arrhythmias
Ischemia-induced ventricular arrhythmias were counted during
the occlusion period and determined in accordance with the Lambeth
Conventions [29]. Ventricular ectopic beats (VEBs), ventricular
tachycardia (VT), ventricular ﬁbrillation (VF), multipart forms of
VEBs such as bigeminy, couplet and salvos were counted at separate
episodes [28]. The incidence, time of occurrence and duration of
arrhythmias were used to identify arrhythmias severity according to
the following scoring system [30]; 0: 0–49 VEBs, 1: 50–499 VEBs, 2:
N499 VEBs and/or 1 episode of spontaneously reverting VT or VF, 3:
N1 episode of VT or VF or both with a total duration b60 s, 4: VT or VF
or both 60–120 s total duration, 5: VT or VF or both N120 s duration, 6:
fatal VF starting at N15 min after occlusion, 7: fatal VF starting
between 4 and 14 min 59 s, 8: fatal VF starting between 1 and 3 min
59 s, and 9: fatal VF starting b1 min after occlusion.
2.8. Biochemical analysis
Blood sampleswere collected at the end of each experiment. Plasma
samples were extracted and stored at−70 °C until they were assayed.
The creatine kinase-MB (CK-MB) isoenzyme and lactate dehydrogenase
(LDH) levels were analyzed using ELECSYS System (ELECSYS 2010,
Roche, Germany) and commercial kits (Pars Azmoon, Iran).
Table 1
Hemodynamic parameters.
Groups n Baseline Ischemia Reperfusion
MBP HR RPP MBP HR RPP MBP HR RPP
IR 6 110±4 349±14 37,651±2003 91±4 317±15 32,515±2588 90±5 300±16 31,168±2863
OT 6 108±4 354±8 38,145±1432 102±3 323±12 35,164±2192 98±3 343±11 35,203±1817
IPC 7 114±4 334±10 37,733±1896 98±3 309±16 32,403±1098 100±3 316±11 34,205±1642
IPC+ATO 6 106±4 327±11 36,752±2839 95±4 284±14 30,762±1461 101±6 303±7 32,240±1456
IR+ATO 6 105±3 320±9 35,390±2169 90±3 290±9 31,407±1117 98±5 290±8 32,076±2203
Data are presented as mean±S.E.M. n=number of animals in each group; MAP = mean arterial pressure (mmHg); HR = heart rate (beats/min), RPP = rate pressure product
(beats/min mmHg); IR = ischemia reperfusion; OT = oxytocin; IPC = ischemic preconditioning; and ATO = atosiban.
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Oxytocin, atosiban, 2, 3, 5-triphenyltetrazolium chloride and Evans
blue were obtained from Sigma Chemical Co. (St. Louis, MO, USA).
2.10. Statistical analysis
Statistical analysis of hemodynamic data within and between
groups was performed with two-way analysis of variance. Differences
in infarct size, CK-MB and LDH plasma levels were determined by one-
way analysis of variance. Groups were individually compared using
Dunnet's test. Arrhythmia scores were analyzed with Kruskal–Wallis
test, and the incidences of VT or VF were compared by Fisher exact
test. All data were expressed as mean±S.E.M. Statistical signiﬁcance
was deﬁned as Pb0.05.
3. Results
3.1. Hemodynamic data
The results depicted in Table 1 show that heart rate (HR), mean
arterial pressure (MAP) and rate pressure product (RPP) slightly but
not signiﬁcantly decreased in all groups at the end of ischemia and
reperfusion compared to their baseline. There were no signiﬁcant
differences of hemodynamic parameters in baseline, ischemia and
reperfusion periods among groups (Table 1).
3.2. Area at risk and infarct size measurement
AAR was not different among groups. Infarct size was decreased
signiﬁcantly in OT and IPC groups compared to IR (Pb0.05).Fig. 2.Myocardial area at risk (AAR/V%) and infarct size (IS/AAR%) in IR, OT, IPC, IPC+
ATO and IR+ATO groups. Data are presented as mean±S.E.M. *Pb0.05 vs. IR group.
#Pb0.05 vs. IPC group. $Pb0.05 vs. OT group. IR = ischemia–reperfusion; OT =
oxytocin; IPC = ischemic preconditioning; and ATO = atosiban.Administration of atosiban in IPC+ATO group increased infarct size
to 39±0.9% in comparison with OT and IPC groups (Pb0.05) (Fig. 2).
3.3. Ventricular arrhythmias during ischemia
3.3.1. Severity of arrhythmias
The use of OT and IPC prior to ischemia signiﬁcantly declined
ventricular arrhythmias severity in compared to IR group (Pb0.05).
Administration of atosiban in IPC+ATO group intensiﬁed severity of
arrhythmias in compared with OT and IPC groups (Pb0.05) (Fig. 3).
3.3.2. Incidences of VT and VF
In IR group, all animals were experienced VT, while VF occurred in
33% of hearts. The use of OT and IPC attenuated VT incidence to 50%
and 43%, respectively (Pb0.05) and abolished VF incidence complete-
ly. In comparison with OT and IPC groups, administration of atosiban
restored the incidence of VT to 100% and VF to 50% in IPC+ATO group
(Pb0.05). Atosiban did not change signiﬁcantly incidences of VT and
VF in comparison with IR group (Fig. 4).
3.4. Biochemical analysis
TheuseofOT and IPC signiﬁcantly decreasedCK-MBandLDHplasma
levels in comparison with IR group at the end of reperfusion period
(Pb0.05). Atosiban administration in IPC+ATO group signiﬁcantly
increased CK-MB and LDH plasma levels (Pb0.05) (Fig. 5A and B).
4. Discussion
IPC has powerful cardioprotective effects against ischemia, which
remains unmatched by other therapeutic agents. Our study showsFig. 3. Distribution of the arrhythmia score during 25 min ischemia in IR, OT, IPC, IPC+
ATO and IR+ATO groups. Data are presented as mean±S.E.M. *Pb0.05 vs. IR group.
#Pb0.05 vs. IPC group. $Pb0.05 vs. OT group. IR = ischemia–reperfusion; OT =
oxytocin; IPC = ischemic preconditioning; and ATO = atosiban.
Fig. 4. The incidence of ventricular ﬁbrillation (VF) and ventricular tachycardia (VT)
during 25 min ischemia in IR, OT, IPC, IPC+ATO and IR+ATO groups. Data are
presented as mean±S.E.M. *Pb0.05 vs. IR group. #Pb0.05 vs. IPC group. $Pb0.05 vs. OT
group. IR = ischemia–reperfusion; OT = oxytocin; IPC = ischemic preconditioning;
and ATO = atosiban.
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Fig. 5. The effects of OT, IPC and ATO on plasma levels of LDH (A) and CK–MB (B) in IR,
OT, IPC, IPC+ATO and IR+ATO groups. Data are presented as mean±S.E.M. *Pb0.05
vs. IR group. #Pb0.05 vs. IPC group. $Pb0.05 vs. OT group. IR = ischemia–reperfusion;
OT = oxytocin; IPC = ischemic preconditioning; and ATO = atosiban.
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receptor selective antagonist. This suggests that endogenous OT may
be involved in the protective effects of IPC in the intact rat heart.
More recently, OT has been considered to be a cardiovascular
hormone [14,15]. It is produced and released by the heart and acts on
its receptors to decrease cardiac rate and force of contraction [15].
Costa-E-Sousa et al. [24] have reported that endogenous OT may play
an important role in regulation of vascular and cardiac function. The
results of the present study show that pretreatment with OT receptor
antagonist can prevent IPC-induced cardioprotection in the anesthe-
tized rat. We also showed that atosiban administration cannot induce
signiﬁcant changes on hemodynamic parameters. This suggests that
endogenous OT preconditioning effects on myocardial injury may not
be related to hemodynamic parameters. One possible mechanism is
that OT modulates energy demand and myocardium contractile state
followed by a myocardial oxygen consumption reduction [31]. Recent
study also showed exogenous OT has direct negative chronotropic
effects [24]. Slow heart rate causes a decrease in myocardial
consumption of oxygen, nutrients and an increase in subendocardial
blood ﬂow per beat that can improve regional contractile function
[10]. It may be important for oxytocin cardioprotective effects in
experimental condition.
In our study, changes in infarct size correlate well with the
antiarrhythmic effects of IPC. Therefore, it appears that the extent of
myocardial infarction may directly affect arrhythmia. Blockade of OT
receptor rather offsets endogenous OT effects on ventricular arrhyth-
mias and infarct size. On the other hand administration of atosiban
signiﬁcantly abolished the cardioprotective effects of IPC, but it did
not completely increase infarct size to the level of IR group which
means other mechanisms may be involved in IPC. However, the
mechanism of antiarrhythmic effects may be different. The present
investigation is in agreement with previous reports in which the
cardioprotection induced by exogenous OT could be abolished when
rats were treated with atosiban prior to ischemia [10,27,28].
Elevated level of CK-MB as a biochemical marker of myocyte
necrosis [32] has also been increased by atosiban when administrated
just before IPC. Increased serum LDH level, a systemic tissue damage
marker [33], has been raised. OT treatment has also attenuated the
renal IR-induced LDH response [26]. Similarly elevated serum LDH
level in acetic acid-induced colitis was signiﬁcantly decreased by OT
treatment [34]. All of these ﬁndings suggest that endogenous OT
exerts beneﬁcial effects on the ischemic reperfused hearts. Since the
effects of endogenous OT occur in the absence of detectable changes in
systemic and coronary hemodynamics, it's in vivo effects on ischemic
myocardium are likely depends upon direct cytoprotection at the
cellular level. There are only limited numbers of published studies
showing the anti-ischemic effects of OT [25,26,35]. Based on anti-
inﬂammatory actions and preventing free radical damaging cascades
[34]. Its protective effect in colon, liver and kidney appears to be
dependent on its inhibitory effect on neutrophil inﬁltration and
associated production of reactive oxygen species [25,26,36]. Recently,
a study also showed that OT may exert an alternate role by regulating
and maintaining a balance of anti-inﬂammatory and pro-inﬂamma-
tory cytokines within the injured heart in rat [37]. Accordingly, the
anti-inﬂammation, antioxidant effect, and anti-inﬂammatory and
pro-inﬂammatory cytokines balance of OT on cardiac tissue may be
the cause of its protection.
Themechanism of protection of endogenous OT in cardiomyocytes
requires further study. Nevertheless, the cytoprotective effect of
endogenous OT on cardiomyocytes could have important therapeutic
implications. Our study shows that endogenous OT can augment the
effect of ischemic preconditioning. These results suggest that endog-
enous OT is not a major mediator of ischemic preconditioning, but the
effect of ischemic preconditioning can be enhanced by endogenousOT.
The major ﬁnding of the present study is that endogenous OT plays an
important role in the cardioprotective effects of IPC.
90 A.M. Alizadeh et al. / Regulatory Peptides 167 (2011) 86–905. Conclusion
In conclusion, this study shows that, in part, the cardioprotective
effects of IPC can be induced by endogenous OT.
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